Rejuvenated T cells for off-the-shelf therapy
A renewable iPSC platform that preserves antigen specificity and supports repeatable production
Ando Therapeutics is a clinical-stage biotechnology company developing off-the-shelf T cell therapies for cancer and autoimmune diseases.
Founded by Professors Hiro Nakauchi and Miki Ando, the company builds on pioneering research in stem cell biology and T cell rejuvenation to make cell therapies more effective, durable, and accessible.
Our technology
Our platform uses induced pluripotent stem cells (iPSCs) to generate rejuvenated T cells, or “rejTs.” By reprogramming antigen-specific T cells into iPSCs and differentiating them back into T cells, we restore their capacity to expand while preserving their ability to recognize disease-related targets.
We combine this approach with genetic engineering to enhance target recognition and reduce immune rejection. A renewable iPSC source supports consistent, scalable manufacturing, with the goal of providing ready-to-use therapies for many patients.
Antigen-specific T cells- Reprogram
Renewable iPSCs- Engineer
Engineered iPSCs- Establish bank
Master cell bank- Differentiate & expand
Rejuvenated T cellsOff-the-shelf supply
Rejuvenated function
Restore expansion capacity while preserving antigen recognition
Complementary targeting
Native TCR recognition plus engineered CAR targeting
Immune-stealth engineering
HLA engineering to reduce host immune recognition
Scalable supply
A renewable bank for repeatable production across multiple patients